Written By | Torch Media Africa
A Kentucky lab discovers the brain's own immune cells — not the infamous plaques — are stealing two hours of sleep a night, and silencing them brings the sleep roaring back
Search
LEXINGTON, Ky.
Picture a small fire breaking out in your kitchen. It's contained, manageable — the kind of thing you could put out yourself with the right tool. But before you get the chance, the sprinkler system floods the entire house, ruining everything you own in the process of "protecting" it.
That, according to a stunning new study out of the University of Kentucky, is essentially what happens inside the brain of every person living with Alzheimer's disease every single night. And for the first time, scientists say they've found the sprinkler valve — and figured out how to shut it off.
The discovery, published this month in the journal Alzheimer's & Dementia, upends decades of assumptions about one of the disease's cruelest side effects: the profound, exhausting sleep loss that steals rest from millions of patients and, researchers now believe, actively accelerates their decline. The culprit isn't the infamous sticky amyloid plaques that have dominated Alzheimer's research for a generation. It's the brain's own immune cells — and when researchers temporarily switched those cells off in mice, more than two hours of lost sleep came flooding back, without a single plaque disappearing.
"Mind-blowing" is how the study's senior author described the results. It might just be the most important thing to happen in Alzheimer's sleep research in years.
THE FIRE AND THE SPRINKLERS
For decades, doctors and scientists have operated under a fairly simple theory: amyloid plaques — the sticky protein clumps that build up between neurons in Alzheimer's patients — physically gum up the brain's machinery, and that physical damage, plus the death of neurons the plaques cause, is what wrecks sleep. Fix the plaques, the thinking went, and eventually you'd fix the sleep.
Shannon L. Macauley, an associate professor of physiology at the University of Kentucky's College of Medicine, and Nicholas J. Constantino, a recently graduated doctoral student in her lab, weren't so sure. Working out of the university's Sanders-Brown Center on Aging, the pair set out to test whether the disruption was really coming from the plaques themselves — or from something responding to the plaques.
That something turned out to be microglia: the brain's resident immune cells, whose job is to patrol for damage and clean up debris, plaques included. It's a protective function in theory. In practice, the Kentucky team found, microglia react to amyloid plaques by triggering an elaborate cascade of brain inflammation — one that never really calms down, night after night, for the rest of a patient's life.
"Basically, we showed that it is not the plaques themselves, or solely dysfunctional neurons, that cause sleep loss but actually microglia," Macauley said. "Microglia are immune cells that, when they respond to plaques, kick off this elaborate cascade of inflammation, as if the microglia are partying all night, and keeping the brain awake."
In other words: the smoke alarm never stops going off, so the sprinklers never stop running, and the house — the sleeping, healing, memory-consolidating brain — never gets a chance to dry out.
INSIDE THE LAB: WATCHING BRAINWAVES AND LIGHTING UP GHOST TISSUE
To untangle cause from effect, Macauley's team compared two groups of mice: those genetically engineered to develop Alzheimer's-like amyloid plaques, and normal "wild-type" mice that aged naturally without the disease. They studied both groups at two life stages — six months, when plaques first begin appearing, and 18 months, representing advanced, late-stage disease.
The mice wore tiny head-mounted sensors recording electroencephalography (EEG) and electromyography (EMG) — essentially an electrical fingerprint of brain activity paired with a muscle-movement tracker — allowing researchers to pinpoint, second by second, exactly when each mouse was in deep restorative sleep, dreaming sleep, or fully awake. Using a specialized mathematical technique called Fitting Oscillations and One Over Frequency, the team was able to separate the brain's rhythmic "brainwave" activity from the underlying background electrical noise — essentially checking whether the brain's engine was idling too hot even while the animal was supposedly at rest.
Then came the visual proof. Using a cutting-edge imaging method called light-sheet microscopy, researchers rendered whole sections of mouse brain tissue completely transparent and scanned them with a thin sheet of laser light, building high-resolution 3D maps that showed, all at once, the entire landscape of amyloid plaques and immune cells lighting up together — a technique Macauley described as watching exactly where the microglia were "partying all night."
Finally, to prove the immune cells were actually causing the sleep loss rather than just being present alongside it, the team turned to a drug called Pexidartinib, originally developed for cancer treatment. The medication works by blocking a signal microglia need to survive. After feeding it to the mice for 14 days, the researchers had eliminated 87% of the brain's immune cells — and then watched to see whether sleep would return. It did. Dramatically.
TWO HOURS, GIVEN BACK
With the microglia knocked back, mice with Alzheimer's pathology gained more than two hours of sleep per night — specifically, longer stretches of deep, restorative non-REM sleep, the kind associated with memory consolidation and the brain's overnight "cleaning cycle." Crucially, none of the amyloid plaques in their brains had shrunk or disappeared. The sleep came back even though the fire in the kitchen was still burning; the researchers had simply found a way to shut off the sprinklers without putting out the flames.
"That restorative sleep is super important for physical repair, learning and memory and washing out the toxins of the day," Macauley said. "When Alzheimer's patients lose this stage, they lose their brain's primary cleaning cycle, creating a feed-forward loop that may drive further damage."
Perhaps the most surprising twist in the data: the researchers expected sleep problems to get steadily worse as plaque buildup increased between six and 18 months. Instead, they found what they're calling a "ceiling effect" — sleep disruption that appeared early, as soon as plaques first showed up, and then simply plateaued, even as plaque levels more than doubled by later life stages.
"I expected that as plaque burden became more severe, sleep disruption would also worsen," said Constantino, the study's first author. "The disruptions in sleep and cortical EEG activity that occur at six months, when plaques first emerge, did not worsen by 18 months, despite more than double the amount of plaque burden."
The implication is striking: it's not the accumulating pile of plaques doing the damage over time — it's the initial inflammatory alarm triggered by the first plaques that sets the sleep-destroying pattern in motion, and that pattern then seems to lock in place regardless of how much worse the underlying disease gets.
The study also helped clarify a distinction that had long confused researchers trying to separate ordinary aging from Alzheimer's-specific decline. Normal aging, the team found, mostly chips away at REM sleep — the dreaming stage tied to memory processing. Alzheimer's disease, by contrast, specifically targets non-REM sleep, the deep, restorative stage where the brain does its nightly repair work. That distinction matters enormously for doctors trying to figure out whether a patient's sleep troubles are just a normal part of getting older or an early warning sign of something more serious.
A "PARADIGM SHIFTING" DISCOVERY
Macauley didn't mince words about what the finding means for the field. She called it "paradigm shifting" — a rare label in a research area that has, for thirty years, largely revolved around one single villain: amyloid plaques. Billions of research dollars and dozens of failed clinical trials have chased the idea that clearing plaques from the brain is the key to treating Alzheimer's. This study suggests that, at least for one of the disease's most debilitating symptoms, the plaques may be almost beside the point.
That reframing opens an entirely new category of potential treatment — one that doesn't require the extraordinarily difficult task of clearing amyloid from a living human brain, something the pharmaceutical industry has struggled with for decades with limited success. Instead, it points toward calming an overactive immune response, a target that in principle could be reached with drugs already sitting on pharmacy shelves.
Macauley's lab is already chasing that possibility. Rather than eliminating microglia entirely — not a realistic or safe option in human patients — her team is investigating whether existing, already-approved medications might be repurposed to simply calm the cells down. Two candidates under early investigation: Metformin, the decades-old diabetes drug taken by millions of Americans, and Stiripentol, an antiseizure medication. Both are being studied for their potential to change how microglia use cellular fuel, potentially cooling their tendency to overreact without knocking them out of commission altogether.
"If we can target that process, it might help with quality of life, attention, cognition and confusion," Macauley said.
The team also believes their EEG-based measurements could eventually become a practical diagnostic tool in their own right. Because the researchers identified specific electrical brainwave signatures that distinguish Alzheimer's-related sleep disruption from ordinary aging, Macauley suggested that portable, take-home EEG devices could someday offer doctors a cheap, noninvasive way to screen patients for early Alzheimer's-related changes — without requiring an expensive brain scan or an hours-long drive to a specialized memory clinic.
"Portable EEG systems could allow us to monitor people in their home environments and potentially screen for changes associated with an Alzheimer's disease, without the initial need for expensive or invasive tests," Macauley said, adding that the approach could let doctors at small local clinics across Kentucky flag at-risk patients before they ever need to travel to a major hospital for specialized testing.
EXPERT PERSPECTIVE
Sleep disruption is not a minor footnote in the Alzheimer's story — it affects between roughly a quarter and nearly half of all patients, according to the researchers, and it tends to be one of the most disabling and caregiver-exhausting symptoms of the disease, often cited as a leading reason families are eventually forced to move a loved one into full-time residential care. Poor sleep and Alzheimer's have also long been suspected to feed each other in a vicious cycle: bad sleep may accelerate the buildup of toxic brain proteins, while those proteins, this new study suggests, in turn provoke the immune response that further wrecks sleep.
Macauley credits her lab's willingness to challenge the field's dominant assumption — that plaques alone were the whole story — to a culture of encouraging students to take intellectual risks. She keeps a Wayne Gretzky quote in her office: "You miss 100% of the shots you don't take." Constantino, the study's first author, said that mindset shaped how the research team responded when their original hypothesis about worsening sleep loss turned out to be wrong.
"Dr. Macauley has also taught me to embrace uncertainty and failure as part of the scientific process," Constantino said. "Some of the most interesting studies I have been a part of emerged because our original hypothesis was wrong."
WHAT THIS MEANS FOR YOU
For the roughly seven million Americans living with Alzheimer's disease today, and the millions more caring for them, this research doesn't offer an immediate cure — the findings so far are in mice, not people, and any human treatment based on calming overactive microglia is still years away from a doctor's office. But it does offer something that has been in short supply in Alzheimer's research for a long time: a genuinely new direction, aimed squarely at improving quality of life right now, rather than waiting on the elusive goal of clearing plaques from the brain entirely.
If you have a family member struggling with disrupted, fragmented sleep and an Alzheimer's diagnosis, this research is a reminder that their sleep problems are not simply an unfixable symptom of brain damage — they may be driven by an active, and potentially treatable, inflammatory process. That reframing matters for how families and doctors think about managing the disease day to day, and it may eventually open the door to treatments, potentially using drugs that are already approved and on the market for other conditions, that could restore some of what the disease steals long before a cure for the underlying condition is found.
It's also a useful reminder for anyone concerned about a parent's or grandparent's memory: because the researchers found that Alzheimer's-related sleep disruption shows a distinctive pattern compared with normal aging, unusually severe changes in a loved one's sleep — not just occasional restlessness, but a real collapse in deep, restorative sleep — may be worth flagging to a doctor as a potential early sign worth investigating, rather than dismissing as an ordinary part of growing older.
THE BOTTOM LINE
For three decades, Alzheimer's research has been dominated by a single question: how do we clear the plaques? The University of Kentucky team's discovery suggests that, at least when it comes to giving patients their sleep back, that may be the wrong question entirely. The real damage may be coming from the brain's own overzealous defense system — sprinklers that never learned when to shut off. Turn down that response, this study suggests, and you might just give patients and their families back something that has felt, for years, impossibly out of reach: a good night's sleep.
